Skye Bioscience, Inc. (SKYE): Nasdaq/NYSE listing notice — Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity

Skye Bioscience, Inc.

Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.
Nasdaq gave 45 days (until June 29, 2026) to submit a compliance plan; extension possible to Nov 9, 2026.
No immediate impact on trading; stock continues to trade under 'SKYE'.
Company is evaluating alternative courses of action to regain compliance; no assurance of success.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Skye Bioscience, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5810(c)(2)(C)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A), 5810(c)(2)(C)

Exact text from the filing

May 13, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-035535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.